ORIC Presents Enozertinib Data and Plans Global Phase 3 Trial
ORIC reported 84% confirmed systemic ORR and 70% confirmed intracranial ORR for enozertinib in first-line NSCLC patients with EGFR atypical mutations. The company plans to advance the drug into a global Phase 3 trial.
Story updates
07:18:32 AM UTC
SquawkNews
ORIC reported Phase 1b data for enozertinib in 1L EGFR atypical NSCLC with 84% confirmed systemic ORR and 70% confirmed intracranial ORR, and plans to start the Redwood-1 global Phase 3 trial in 1H 2027.Material DetailsContext by AI AnalystORIC is transitioning to late-stage with enozertinib after…